Industry-Sponsored Research Week
University-Industry Engagement Advisor

Expert Strategies for Patenting and Licensing Early-Stage Drug Discoveries

By David Schwartz
Published: October 19th, 2021

Universities are devoting tens of millions of research dollars toward drug discovery activity with no sign of a slowdown, and biopharma companies are increasingly relying on academia to fill their pipelines. The need for effective IP protection has never been greater, but with very early-stage drug candidates, molecules and compounds, that can be a tricky proposition. If you don’t have a firm understanding of the criteria for patentability, essential claims language, data requirements, and how sponsored research and research partnerships come into play, your entire investment and your researchers’ years of hard work could go up in the smoke of invalidity challenges or licensee disinterest.

On the other hand, a well-crafted patent strategy and a solid plan for licensing can ensure your researchers and your university reap the benefits of these promising discoveries.

That’s why Tech Transfer Central’s Distance Learning Division is teaming up with Lisa Mueller, a patent attorney with deep experience in biopharma patent law and licensing, for this critically important webinar: Expert Strategies for Patenting and Licensing Early-Stage Drug Discoveries, scheduled for November 9th. Ms. Mueller will explore in detail patent strategies in academic drug discovery. Specifically, the criteria for patentability, including the patenting of salts, solvates, polymorphs and prodrugs as well as drug repurposing.

For complete program details or to register, click here.

Also coming soon:

Posted under: University-Industry Engagement Week, Webinars

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment